Last updated: March 14, 2024
Sponsor: Joachim Zdolsek
Overall Status: Active - Recruiting
Phase
4
Condition
Neoplasms
Urologic Cancer
Cancer
Treatment
albumin 5%
albumin 20%
acetated Ringers
Clinical Study ID
NCT05726136
FC-VE
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Written consent to participate in the study
- For women: relevant contraceptive, menopausal or a negative pregnancy test.
- ASA category I to III
- Laparoscopic abdominal surgery, with a duration of at least 90 minutes.
- 18 to 80 years
Exclusion
Exclusion Criteria:
- Patients with known cardiac failure
- <18 or >80 years
- known allergy to albumin
- extracellular hyperhydration or hypervolemia
- kidney failure
- pregnancy or planned pregnancy
Study Design
Total Participants: 60
Treatment Group(s): 3
Primary Treatment: albumin 5%
Phase: 4
Study Start date:
October 23, 2023
Estimated Completion Date:
October 31, 2025
Study Description
Connect with a study center
Vrinnevi Hospital
Norrköping, Östergötland 60379
SwedenActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.